Home › NCT07492160

Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms

Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss: A Pilot and Randomized Controlled Trial

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* Pregnant people aged 18 years or older
* Gestational age between 12 and 18 weeks
* Undergoing treatment for spontaneous or induced abortion at Maimonides Medical Center
* Able to provide informed consent
* Willing and able to complete study surveys

Exclusion Criteria:

* Prior mastectomy
* Currently breastfeeding
* Current use of a dopamine agonist or dopamine antagonist medication
* Known contraindication to Cabergoline according to the medication prescribing information

About the study

The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are:

Does cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss?

Does cabergoline reduce the severity of breast symptoms and associated bother compared with placebo?

Researchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss.

Participants will:

Complete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure

Receive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure

Complete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother

A subset of participants will provide blood samples at selected time points to measure serum prolactin levels

What is being tested

• Cabergoline (drug)
• Placebo (drug)

Sponsor: Jefferson Drapkin · Participants: 348 · Started: Mar 16, 2026

Contact the study team

• June Ng, MD · Phone: 718-283-7048
• Olivia Sher, MPH · Phone: 718-283-7962

Official record on ClinicalTrials.gov — NCT07492160

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.